BioDuro, a global Contract Research, Development, and Manufacturing Organization, announced a partnership with Silicogenix (SGX), the pioneer of fit-for-purpose small molecule design technology that empowers polypharmacology and non-traditional drug development. 

The collaboration combines BioDuro’s leading drug discovery platform with SGX’s frameworks to lower the cost and time barriers in developing complex therapies.

SGX’s technology enables biopharma companies to initiate and test new therapies, including possible combinations with standard-of-care treatments, due to their ability to access most of the human proteome. Leveraging the leading drug discovery platform, BioDuro delivers various complex molecules at speed and accelerates the path from drug discovery through to preclinical at a lower cost.

“We are focused on the continued innovation of our fully integrated services to help meet growing demand for early drug discovery,” said Dr. Subas Sakya, Chief Scientific Officer at BioDuro. “We are excited to partner with SGX to enable an alternative path for new drug discovery, propelling first-in-class therapeutics with the potential to save lives.”

“This is a pivotal moment for the biopharmaceutical industry, and this partnership is a significant step forward for how novel treatments for complex and rare diseases can be quickly brought to market,” said Dr. Shailesh Date, Co-founder of Silicogenix.